Equities

Mediwound Ltd

Mediwound Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)15.10
  • Today's Change-0.46 / -2.96%
  • Shares traded58.77k
  • 1 Year change+20.80%
  • Beta0.9396
Data delayed at least 15 minutes, as of Mar 27 2024 20:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.

  • Revenue in USD (TTM)18.69m
  • Net income in USD-6.72m
  • Incorporated2000
  • Employees100.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
aTyr Pharma Inc353.00k-50.39m135.50m56.00--1.40--383.85-0.9537-0.95370.00661.430.0033--0.04976,303.57-46.57-45.45-54.04-52.74-----14,276.77-784.19----0.0208---96.60---11.14--47.98--
Ocean Biomedical Holdings Inc0.00-45.58m138.39m9.00---------1.40-1.400.00-0.0642------0.00-----------------------------612.50------
Relmada Therapeutics Inc0.00-98.79m138.50m20.00--1.62-----3.28-3.280.002.840.00----0.00-78.89---87.51--------------0.00------37.09------
Coya Therapeutics Inc6.00m-7.99m140.34m8.00--3.90--23.38-0.8219-0.82190.59062.470.2417----750,276.30-32.17---39.17-------133.08------0.00------34.77------
Beyondspring Inc1.55m-27.51m141.29m67.00------91.16-0.7043-0.70430.0397-0.46370.0321----21,232.88-60.79-91.82-81.96-118.82-----1,895.29-9,233.73--------0.00--48.15---14.86--
Mediwound Ltd18.69m-6.72m143.32m100.00--4.41--7.67-0.768-0.7682.073.430.32096.282.87186,860.00-11.53-24.48-14.35-32.9219.1543.27-35.94-38.434.33--0.1674---29.4840.6065.73--64.66--
Acrivon Therapeutics Inc0.00-50.07m143.49m56.00--1.03-----2.28-2.280.006.250.00----0.00-41.93---44.88--------------0.00-------91.88------
Nuvectis Pharma Inc0.00-22.26m148.19m13.00--11.91-----1.42-1.420.000.70050.00----0.00-112.45---168.51--------------0.00-------16.64------
Armata Pharmaceuticals Inc4.53m-69.05m148.21m66.00------32.72-1.91-1.910.1255-0.88770.0466----68,621.21-71.11-59.78-90.34-72.70-----1,524.51-1,113.72---1.681.64---17.77---87.03--184.10--
CytomX Therapeutics Inc101.21m-569.00k148.31m120.00----92.351.47-0.0191-0.01911.37-0.70490.4375--5.14843,450.00-0.246-21.53-0.7382-32.32-----0.5622-100.38--------90.3811.2199.43---26.01--
Galectin Therapeutics Inc0.00-45.44m149.06m12.00---------0.763-0.7630.00-0.82250.00----0.00-208.11-84.71-417.72-104.98-----------15.305.96-------26.63------
Syros Pharmaceuticals Inc8.80m-104.96m149.85m117.003.843.33--17.041.521.520.3651.750.0407--5.1275,170.94-48.54-49.48-57.40-58.43-----1,193.45-700.90----0.5309---36.6568.33-9.35--8.61--
Telomir Pharmaceuticals Inc0.00-4.23m150.57m2.00--69.13-----0.1429-0.14290.000.0736------0.00-------------------3.800.3805-------518.37------
Vor Biopharma Inc0.00-117.86m150.65m168.00--0.9955-----1.75-1.750.002.220.00----0.00-47.38-45.79-50.28-48.98------------0.00-------27.98------
I-Mab ADR3.83m-202.81m150.91m318.00--0.6348--39.45-2.29-2.290.04452.950.0083-------43.84-35.99-53.14-42.08100.00---5,302.03-496.71---42.630.0171--112.48-12.4641.54------
Data as of Mar 27 2024. Currency figures normalised to Mediwound Ltd's reporting currency: US Dollar USD

Institutional shareholders

25.87%Per cent of shares held by top holders
HolderShares% Held
Point72 Asset Management LPas of 31 Dec 2023821.50k8.92%
Rosalind Advisors, Inc.as of 31 Dec 2023606.75k6.59%
DAFNA Capital Management LLCas of 31 Dec 2023257.65k2.80%
Uniplan Investment Counsel, Inc.as of 31 Dec 2023145.27k1.58%
Wells Fargo Clearing Services LLCas of 31 Dec 2023132.10k1.44%
Yelin Lapidot Mutual Fund Management Ltd.as of 31 Dec 2023125.49k1.36%
Sargent Investment Group LLCas of 31 Dec 2023109.19k1.19%
Silverberg Bernstein Capital Management LLCas of 31 Dec 202378.98k0.86%
Renaissance Technologies LLCas of 31 Dec 202355.94k0.61%
Sphera Funds Management Ltd.as of 31 Dec 202348.98k0.53%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.